Status:
UNKNOWN
Glucoside- and Rutinoside-rich Crude Material for Relieving Side Effects of COVID-19 Vaccines
Lead Sponsor:
Taipei Medical University
Conditions:
Vaccine Adverse Reaction
Side-Effect
Eligibility:
All Genders
20-65 years
Phase:
NA
Brief Summary
Urgent vaccine development plus the characteristics of the coronavirus have caused the relatively more safety problems in COVID-19 vaccines than other classic vaccines and unavoidably raises more conc...
Detailed Description
Since the outbreak of Coronavirus Disease-2019 (COVID-19), the size of the infected population continues to expand, and the number of deaths due to the infection continues to climb. Massive vaccinatio...
Eligibility Criteria
Inclusion
- Concious
- Mentally capable
- Can comunicate using Mendalin or Taiwanese dialet
- Agree to join the current trial
Exclusion
- Unable to read the google sheets
- dysphagia
- \> 65 years
Key Trial Info
Start Date :
May 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2023
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT05387252
Start Date
May 31 2022
End Date
May 31 2023
Last Update
May 24 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.